Genmab A/S American Depositary Shares (GMAB)
NASDAQ
Closed
Oct 8, 2026
Day's Range
35.0952 wk Range
23.62Overview - GMAB - Genmab A/S American Depositary Shares
Key Statistics
Valuation
Enterprise Value
24.84B
P/E (Trailing)
‪28.03‬
P/E (Forward)
‪22.21‬
PEG Ratio
‪-3.04‬
Price / Sales (TTM)
‪5.25‬
Price / Book
‪3.53‬
EV / EBITDA
‪18.04‬
Profitability
Gross Margin
‪92.72%‬
Profit Margin
‪19.07%‬
Operating Margin
‪35.23%‬
Return on Assets
‪8.78%‬
Return on Equity
‪13.99%‬
Ownership
Shares Outstanding
61.43M
Float
589.61M
Short % of Shares Outstanding
‪0.81%‬
Held by Insiders
‪0.00%‬
Held by Institutions
‪17.01%‬
Price stats
Beta
‪0.69‬
50-Day Avg
‪32.01‬
200-Day Avg
‪29.53‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
12 analysts
Average price target
‪$ 38.84‬Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - GMAB - Genmab A/S American Depositary Shares
Peers - GMAB - Genmab A/S American Depositary Shares
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- GMABNASDAQGenmab A/S American Depositary Shares21.71BMarket Cap+16.96%52-week change28.03P/E (Trailing)‪19.07%‬Profit Margin
- ARGXNASDAQArgenx SE57.50BMarket Cap+14.28%52-week change34.96P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.29.40BMarket Cap-105.72%52-week change38.35P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share24.34BMarket Cap-8.52%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.99BMarket Cap+7.48%52-week change17.72P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.14BMarket Cap+18.80%52-week change-17.80P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.11.06BMarket Cap+2.75%52-week change154.54P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - GMAB - Genmab A/S American Depositary Shares
About
Genmab A/S American Depositary Shares represents ownership in Genmab A/S, a Denmark-based biotechnology company focused on developing antibody-based therapies. The company’s business centers on human antibody therapeutics for cancer and other serious diseases, with products and product candidates spanning oncology and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
